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Abstract
Background: The 27k Illumina Infinium Methylation Beadchip is a popular high-throughput technology that allows
the methylation state of over 27,000 CpGs to be assayed. While feature selection and classification methods have
been comprehensively explored in the context of gene expression data, relatively little is known as to how best to
perform feature selection or classification in the context of Illumina Infinium methylation data. Given the rising
importance of epigenomics in cancer and other complex genetic diseases, and in view of the upcoming
epigenome wide association studies, it is critical to identify the statistical methods that offer improved inference in
this novel context.
Results: Using a total of 7 large Illumina Infinium 27k Methylation data sets, encompassing over 1,000 samples
from a wide range of tissues, we here provide an evaluation of popular feature selection, dimensional reduction
and classification methods on DNA methylation data. Specifically, we evaluate the effects of variance filtering,
supervised principal components (SPCA) and the choice of DNA methylation quantification measure on
downstream statistical inference. We show that for relatively large sample sizes feature selection using test statistics
is similar for M and b-values, but that in the limit of small sample sizes, M-values allow more reliable identification
of true positives. We also show that the effect of variance filtering on feature selection is study-specific and
dependent on the phenotype of interest and tissue type profiled. Specifically, we find that variance filtering
improves the detection of true positives in studies with large effect sizes, but that it may lead to worse
performance in studies with smaller yet significant effect sizes. In contrast, supervised principal components
improves the statistical power, especially in studies with small effect sizes. We also demonstrate that classification
using the Elastic Net and Support Vector Machine (SVM) clearly outperforms competing methods like LASSO and
SPCA. Finally, in unsupervised modelling of cancer diagnosis, we find that non-negative matrix factorisation (NMF)
clearly outperforms principal components analysis.
Conclusions: Our results highlight the importance of tailoring the feature selection and classification methodology
to the sample size and biological context of the DNA methylation study. The Elastic Net emerges as a powerful
classification algorithm for large-scale DNA methylation studies, while NMF does well in the unsupervised context.
The insights presented here will be useful to any study embarking on large-scale DNA methylation profiling using
Illumina Infinium beadarrays.
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DNA methylation (DNAm) is one of the most important
epigenetic mechanisms regulating gene expression, and
aberrant DNAm has been implicated in the initiation
and progression of human cancers [1,2]. DNAm changes
have also been observed in normal tissue as a function
of age [3-8], and age-associated DNAm markers have
been proposed as early detection or cancer risk markers
[3,6-8]. Proper statistical analysis of genome-wide DNA
methylation profiles is therefore critically important for
the discovery of novel DNAm based biomarkers. How-
ever, the nature of DNA methylation data presents
novel statistical challenges and it is therefore unclear if
popular statistical methods used in the gene expression
community can be translated to the DNAm context [9].
The Illumina Infinium HumanMethylation27 Bead-
Chip assay is a relatively recent high-throughput tech-
nology [10] that allows over 27,000 CpGs to be assayed.
While a growing number of Infinium 27k data sets have
been deposited in the public domain [3,4,11-15], rela-
tively few studies have compared statistical analysis
methods for this platform. In fact, most statistical
reports on Infinium 27k DNAm data have focused on
unsupervised clustering and normalisation methods
[16-19], but as yet no study has performed a compre-
hensive comparison of feature selection and classifica-
tion methods in this type of data. This is surprising
given that feature selection and classification methods
have been extensively explored in the context of gene
expression data, see e.g. [20-33]. Moreover, feature
selection can be of critical importance, as demonstrated
by gene expression studies, where for instance use of
higher order statistics has helped identify important
novel cancer subtypes [24,34]. Given that the high den-
sity Illumina Infinium 450k methylation array is now
starting to be used [10,35] and that this array offers the
coverage and scalability for epigenome wide association
studies (EWAS) [36], it has become a critical and urgent
question to determine how best to perform feature
selection on these beadarrays.
The Illumina Infinium assay utilizes a pair of probes
for each CpG site, one probe for the methylated allele
and the other for the unmethylated version [10]. The
methylation level is then estimated, based on the mea-
sured intensities of this pair of probes. Two quantifica-
tion methods have been proposed to estimate the
methylation level: (i) b-values and (ii) M-values. While
the b-value measures the percentage of methylation at
the given CpG site and is the manufacturer’s recom-
mended measure to use [10], the M-value has recently
been proposed as an alternative measure [19]. The M-
value is defined by the log2 ratio of the intensities of the
methylated to unmethylated probe and has also been
used in the context of other methylation array technolo-
gies [37]. The M-value is also an analogue of the quan-
tity which has been widely used in expression
microarray analysis, although there are two important
differences: in the Infinium DNAm (type I) assay, both
probes are (i) always measured in the same colour chan-
nel, thus dye bias does not need to be adjusted for, and
(ii) the two probes are measured in the same sample. A
recent study based on a titration experiment compared
b a n dM - v a l u e sa n dc o n c l u d e dt h a tM - v a l u e s ,o w i n gt o
their more homoscedastic nature (i.e. variance being
independent of the mean), were a better measure to use
[19]. However, this study was limited to one data set
and feature selection was only investigated using fold-
changes, while statistics and P-values were not
considered.
The purpose of our study is therefore two-fold: (i) to
provide a comprehensive comparison of the perfor-
mance of b and M-value measures in the context of
popular feature selection tools that use actual statistics
to rank features (CpGs), and (ii) to compare the perfor-
mance of some of the most popular feature selection
and classification methods on DNAm data from differ-
ent tissues and correlating with different phenotypes, so
as to gain objective insights into how best to perform
feature selection and classification in this novel context.
To address these goals, we make use of 7 independent
sets of human DNA methylation data, all generated with
the 27K Illumina Infinium platform, encompassing over
1000 samples and representing over 29 million data
points.
Materials and methods
Data sets
The 7 human DNA methylation data sets are sum-
marised in Table 1. All the data were generated using
the Illumina Infinium HumanMethylation27 BeadChip
assay that enables the direct measurement of methyla-
tion at over 27,000 individual cytosines at CpG loci
located primarily in the promoter regions of 14,495
unique genes. All data sets, except the TCGA lung can-
cer set, followed the same quality control and
Table 1 The Illumina Infinium 27 k data sets
Data Set #CpGs Size Tissue #(N, C) Age range Reference
UKOPS 25,642 261 blood (148,113) 50-84 GSE19711
ENDOM 25,998 87 tissue (23,64) 32-90 GSE33422
CERVX 26,698 63 tissue (15,48) 25-92 GSE30760
OVC 27,578 177 tissue (0,177) 25-89 [3]
T1D 22,486 187 blood (187,0) 24-74 GSE20067
BC 24,206 136 tissue (23,113) 31-90 GSE32393
LC 23,067 151 tissue (24,127) NA TCGA
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Page 2 of 14normalisation strategy. Briefly, non background-cor-
rected data was used and only CpGs with intensity
detection P-values less than 0.05 (i.e. significantly higher
intensity above the background determined by the nega-
tive controls) were selected. Inter-array normalisation
correcting for beadchip effects and variations in bisulfite
conversion efficiency were performed using a linear
model framework with explicit adjustment for these fac-
tors, but only if these factors were significantly corre-
lated with PCA/SVD components.
The 7 independent 27k DNAm data sets used in this
paper: UKOPS - UK Ovarian Cancer Population Study:
whole blood samples from women with ovarian cancer
and age-matched healthy controls; ENDOM - normal
endometrium and endometrial cancer; CERVX - normal
cervix and cervical cancer; OVC - ovarian cancer tissue;
T1D - type 1 diabetes: whole blood samples from type-1
diabetics; BC - normal breast tissue and breast cancer;
and LC - normal lung tissue and lung cancer. Number
of CpG probes passing quality control, total number of
samples, tissue type, number of normal/cancer samples,
age-range and reference to data are given. NA: not
available.
Definition of b-value and M-value
In the Illumina Infinium Human Methylation 27k Bead-
Chip assay, bisulphite (BS) converted DNA is amplified,
fragmented and hybridised to the BeadChip arrays, with
each chip accommodating 12 samples as designated by
Sentrix positions A-L. Each interrogated locus is repre-
sented by specific oligomers linked to two bead types,
with one representing the sequence for methylated
DNA (methy) and the other for unmethylated DNA
(unmethy). The methylation status can be measured
either by b-values or M-values.
For each specific CpG site, the b-value is calculated
from the intensity of the methy and unmethy alleles, as
the ratio of the fluorescent signals:
β =M a x

methy,0

/

Max

methy,0

+M a x

unmethy,0

+1 0 0

. (1)
The b-value is a continuous variable between 0
(absent methylation) and 1 (completely methylated)
representing the ratio of the methylated allele to the
combined locus intensity. In contrast, the DNA methy-
lation M-value is calculated as the log2 ratio of the
intensities of the methylated probe to the unmethylated
probe:
M=l o g 2

Max

methy,0

+1

/

Max

unmethy,0

+1

. (2)
The M-value is therefore a continuous variable which
can in principle take on any value on the real line.
Since most interrogated CpG sites have intensities
(methy + unmethy) larger than 1,000, the offset values
(i.e. 100 in b-value and 1 in M-value) have only a small
effect on both measurements. Hence, the relationship
between the b and M-values is approximately logistic:
β =

2∧M

/

2∧M+1

;M=log2

β/1 − β

. (3)
While the b-value has a more intuitive biological
interpretation it suffers from severe heteroscedasticity
(the intrinsic variability is much lower for features
which are either unmethylated or methylated, with
hemi-methylated features exhibiting maximal variance)
[9]. In contrast, the M-value is not directly interpretable
in terms of a methylation percentage, but is more statis-
tically valid for analysis of differential methylation levels
owing to its more homoscedastic nature [19].
Evaluation of feature selection methods
We use a multiple training-test set strategy [31] to com-
pare the true positive detection rates of three different
feature selection methods: (i) without filtering (WF), (ii)
filtering based on variability (VF), (iii) filtering using
supervised principal components (SPCA). Our justifica-
tion for focusing on VF and SPCA is that both methods
have been very popular and effective in the context of
gene expression studies [21,26,27,38]. The performance
measure we use to compare the different feature selec-
tion methods is the estimated positive predictive value
(PPV). That is, for each method we select features sig-
nificantly associated with a phenotype of interest using a
training set, and these features are then evaluated in the
test-set. Those that are also significant in the test set are
called true positives, so the PPV measures the probabil-
ity that a feature declared to be positive in the training
set is a true positive. We point out that strictly speaking
at r u ep o s i t i v ec a no n l yb eaf e a t u r ew h i c hh a sb e e n
s h o w nt ob ep o s i t i v eu s i n gag o l d - s t a n d a r dt e c h n o l o g y .
However, in the absence of such gold-standard data, the
training/test set strategy advocated here provides a sui-
table evaluation framework, since a feature that cross-
validates is more likely to represent a true positive than
one that does not. Moreover, this strategy has already
been successfully used in previous work, see e.g. [21,25].
Thus, for each of the data sets in this study, 50 inde-
pendent training and test sets (training and test set are
always of equal size to ensure that P-values are compar-
able) were randomly generated ensuring similar demo-
graphics for the phenotype of interest in training and
test set. For each training set, a supervised analysis is
used to evaluate the association between each CpG
methylation profile (both b-value and M-value) and the
phenotype of interest. In the case of a continuous phe-
notype (e.g. age) the association is carried out under a
linear regression model framework, while for a binary
phenotype (e.g. cancer/normal status) we use t-statistics.
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in means, and variance of each CpG are recorded.
Variance-filtering (VF) is a feature selection method
that filters the CpGs based on their variability before the
supervised analysis is performed [27,38]. The steps are
I. In each training set, select the 5,000 most variable
CpGs;
II. Rank the 5,000 most variable CpGs according to
the significance of their p-values (from the supervised
analysis) and retain the top ranked 1,500 CpGs (or the
number with p < 0.05 if this is smaller). (We note that
for some studies in the diagnostic setting we retained all
5,000 CpGs to allow for comparable PPV values
between studies).
III. Using stepwise evaluation sets (starting with 50
top CpGs and incrementing in steps of 50 until all top
ranked CpG sites from step II are included in the eva-
luation set), count the number of true positives: i.e. how
m a n yC p G sh a v eas t a t i s t i cp - v a l u e<0 . 0 5i nt h ec o r r e -
sponding test set while exhibiting the same directional
change (sign of statistic) as that in the training set;
IV. For each evaluation set, the positive predictive
value (PPV) is defined as the percentage of CpGs that
are true positives.
Supervised PCA (SPCA) is a powerful semi-supervised
approach for feature selection and classification, first
proposed in [21]. Here we adapt it to the feature selec-
tion context. The steps are:
I. In each training set, perform the supervised analysis
and rank all CpGs according to the significance of their
p-values;
II. Select the top ranked 5,000 CpGs;
III. Run singular value decomposition (SVD) analysis
on the top ranked 5,000 CpGs and find the principal
component most correlated to the phenotype of interest;
IV. Rank the 5000 CpGs according to the absolute
value of their corresponding coefficient in the selected
principal component and further select the 1,500 CpGs
with the largest absolute weights;
V. Use the stepwise evaluation sets and count, for
each evaluation set size, the number of true positives in
the test set using the same criteria as for the VF
method;
VI. For each evaluation set, compute the PPV as
described for VF method.
In the without filtering (WF) method we perform for
each training set the supervised analysis on all ~27,000
CpGs (i.e. all those that pass quality control), select the
top 1500, and then perform the same stepwise evalua-
tion set analysis to estimate PPVs from the p-values in
the corresponding test set.
T h er e s u l to fa p p l y i n ge a c ho ft h e s e3m e t h o d si sa
matrix of PPV values with rows labelling the evaluation
set size (50 to 1500 in increments of 50) and columns
labelling the 50 different runs (i.e. the 50 different train-
ing-test set partitions).
Choice of evaluation set size
Given that different studies may exhibit widely different
operating characteristics (e.g. widely different false dis-
covery rates), even in relation to the same phenotype of
interest, we decided that a more objective comparison
of different feature selection methods across studies
would be facilitated by choosing evaluation set sizes in
each study that result in broadly similar PPV values
across studies. Hence, evaluation set sizes were chosen
so as to minimise differences in PPV between studies,
subject to reasonable constraints on the minimum and
maximum set sizes.
Comparison of classification algorithms
We use the same multiple training-test partition strategy
(50 runs) as used in our feature selection comparison, to
evaluate different classification algorithms. Thus, within
each study, training and test sets were always of the
same size and were balanced for the phenotype of inter-
est. We focused on four different powerful classification
algorithms, which have been popular in the gene expres-
sion field: (i) Supervised PCA (SPCA) [21], (ii) the
LASSO algorithm [40], (iii) the Elastic Net (ELNET)
[32] and (iv) Support Vector Machines (SVM) [33,41].
We used the implementations of these algorithms as
provided in the R-packages superpc, glmnet and e1071.
In the case of SPCA we considered classifiers built from
1 up to 3 principal components, and the number of fea-
tures (minimum was set to 10 and maximum to 5000)
was optimised in the training sets using internal 10-fold
cross-validation. LASSO is a special case of the Elastic
Net with the penalty parameter a = 1 [32]. The Elastic
Net itself was run with a = 0.05 (this choice was moti-
vated by good performance obtained on an independent
27k DNA methylation data set, unpublished data). The
additional penalty ELNET parameter l was estimated in
the training sets using internal 10-fold cross-validations.
The SVM was run with a radial kernel with parameter g
= 3, and with error term ε = 0.1. These SVM parameters
were fixed and not optimised, since we wanted to com-
pare the algorithms at the same level of computational
complexity (i.e. similar computational times to run). We
focused on age as the phenotype of interest since it
represents a challenging scenario of small effect sizes
and yet it is also well established that age has a signifi-
cant impact on DNA methylation patterns [3-5,42].
Since age is a continuous variable, SVM was run in
regression mode, and thus for all methods the predictor
is a continuous score. To evaluate concordance of age
with the predictor in the test sets we used the C-index
(R package Hmisc).
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We considered two popular dimensional reduction algo-
rithms: singular value decomposition (SVD) [43-46], and
non-negative matrix factorization (NMF) [47-51]. In this
work we use the SVD implementation as computed by
the LAPACK/LINPACK routine available in R http://
www.r-project.org. The application of NMF to DNA
methylation is justified due to the positivity of beta-
valued data. To perform NMF, the “NMF” Rp a c k a g e
[52] was used. NMF was run using the “brunet” algo-
rithm and initialised using non-negative double SVD
(NNDSVD). Hence, using this NNDSVD initialisation
NMF yields the same solution under repeated runs and
allows for a direct comparison to SVD. The evaluation
of the 2 algorithms was performed by comparing the
correlations of the inferred components with the pheno-
types of interest (i.e. age and cancer diagnosis), specifi-
cally we derived and compared the corresponding R
2
values under a linear regression model. In the case of
NMF, we needed to specify the number of components
to infer. This number was estimated from the SVD ana-
lysis by comparing the spectral eigenvalues to the corre-
sponding ones obtained by randomly permuting
elements in the data matrix. This number was also the
number of SVD components used when evaluating cor-
relations with the phenotype of interest.
Results
The signal to noise and signal strength landscape of DNA
methylation studies
One of the aims of this study is to compare different
feature selection and quantification methods in relation
to important study-specific parameters. One of these
parameters is the typical effect size of the study. In the
case of a binary phenotype, the effect size of a CpG is
defined, loosely speaking, as the ratio of the difference
in means between the two phenotypes to a pooled stan-
dard deviation. In other words, it can be thought of as a
signal to noise ratio, where the noise captures both bio-
logical and technical variation. Another important para-
meter to take into consideration in any association
analysis is the number of features with an effect size lar-
ger than some significance threshold. Thus, in this study
we ask if the effect size of CpGs associated with a phe-
notype of interest ("signal to noise ratio"-SNR) and their
number ("signal strength”) have an impact on the per-
formance of the different feature selection methods and
if this depends on the methylation measure (i.e. beta or
M-values) used. In order to consider a wide range of
different effect sizes and signal strengths, we considered
two main phenotypes: cancer/normal status (diagnostic
setting) and age; and two different tissue types: epithelial
tissue and whole blood. The corresponding 27k data sets
used in this study are summarised in Table 1. We
verified that these studies exhibited a wide range of dif-
ferent effect sizes and signal strengths, depending largely
on tissue type (Figure 1, Table 2). For instance, we
observed, as expected, that cancer diagnostic DNAm
markers in epithelial tissue have large SNRs and signal
strengths, in contrast to cancer diagnostic markers in
blood, which, while numerous, were characterised by
much smaller effect sizes (Figure 1A-B). This fits in with
the expectation that cancer associated changes in whole
blood reflect mostly changes in the underlying blood
cell type composition [11]. In stark contrast to diagnos-
tic markers, we observed that age has a relatively much
weaker impact on DNAm patterns (Figure 1C-D), and
therefore estimated effect sizes were also smaller (Table
2). The signal strength of age-associated CpGs also var-
ied depending on the tissue in which they were mea-
sured (Table 2).
M-values significantly outperform b values but only in
the small sample size limit
A previous study based on a titration experiment advo-
cated the use of M-values over b values, since M-values
exhibit less heteroscedasticity [19]. However, this study
only used fold-changes to rank features. It is therefore
unclear if results differ had the features been ranked
using statistics. Thus, we asked if using b-values or M-
values to quantify methylation has a differential impact
on the statistics of differential methylation and on the
positive predictive value (PPV).
First, we verified that in our data sets, b values were
highly heteroscedastic, with very low variability at the
extremes of the beta-scale, while M-values were
approximately homoscedastic (Additional file 1). Using
t-statistics and q-values to estimate the false discovery
rate (FDR) at different p-value thresholds and using all
available samples (see Table 1), we observed however
that the difference in FDRs between b and M-values
within each study was very minor (Additional file 2).
Next, we compared the PPVs obtained using either b or
M-values using a multiple 50% training 50% test set
strategy where features were ranked according to their
t-statistics (Materials & Methods). Because for a given
methylation measure we observed substantial differences
in FDR rates between studies, in some cases even
between studies that looked at the same phenotype of
interest and tissue type, we decided to choose evaluation
set sizes specific to each study to ensure that PPV values
were as similar across studies as possible (Materials &
Methods, Additional file 3).
In most studies there was no appreciable difference in
the PPV between b and M- values and the absolute
magnitude of the t-test statistics of the top ranked CpGs
were also very similar (Additional file 4). To study the
dependency on sample size we considered again a
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training and test sets where the number of samples of
each phenotype was low (either 2 to 3 samples). Since
ordinary t-statistics can not be used in this small sample
size limit, we used instead a popular empirical Bayes
approach to rank features according to a regularized t-
statistic [53]. In this small sample size limit, we observed
that the PPV was significantly improved when using M-
values, in some instances by at least 10% (Figure 2A).
Interestingly, using 50% training/test partitions, corre-
sponding to the largest possible sample sizes, the PPV
for M-values was still higher than for b-values, but only
by at most 2% (Figure 2B). However, for larger sample
sizes, PPV values were close to 1 and thus differences
between M-values and b-values would naturally be
smaller. Thus, the improved performance of M-values
over b- v a l u e si sm a i n l yd u et ot h eu s eo fr e g u l a r i z e dt -
statistics, since we also observed that in the large sample
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Figure 1 Example beta-value methylation profiles of top ranked cancer diagnostic associated CpGs in A) UKOPS (whole blood)
(cg20792833) and B) ENDOM (endometrial tissue) (cg19664945) with the x-axis labelling the sample and the cancer (blue) and normal
(orange) status. y-axis labels the beta-value. Similarly, example beta-value methylation profiles of top ranked age-associated CpGs in C) T1D
(whole blood) (cg22736354) and D) OVC (ovarian cancer tissue) (cg25763788), with x-axis labeling the age of the samples. In all 4 panels we
provide the t-test statistic and P-values of association between the beta-value and the phenotype of interest.
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Page 6 of 14size limit ordinary t-statistics performed equally well
irrespective of M-value or b-value basis (Additional file
4). We also observed that in the large sample size limit,
ordinary t-statistics performed similarly if not better
than regularized t-statistics (Figure 2 & Additional file
4). Thus, given that b-values are more directly interpre-
table and that in this work we are mostly interested in
the performance for relatively large sample sizes, we
henceforth focus mainly on b-values.
Variance filtering (VF) can significantly reduce the PPV in
the setting of small effect sizes
Next, we evaluated the effect of filtering CpGs based on
variance prior to performing the supervised analysis.
Variance filtering has been a very popular feature selec-
tion tool in gene expression studies (see e.g. [27,38]),
and it has been shown to improve the detection rate of
true positives [21,27]. Hence, we asked if the same result
holds in the context of DNA methylation data.
We observed that filtering based on variance improved
the PPV in 3 of the 5 cancer/normal studies and in 3 of
the 6 studies when age was the phenotype of interest
(Figures 3A and 3B). In the age-setting, VF did worse
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Figure 2 A) PPV comparison between M-values and b-values in the small sample size limit and in the diagnostic setting. Evaluation set
sizes were the top 200, 1500, 2500, 1500, and 3000 diagnosis-associated-CpGs for UKOPS, ENDOM, CERVX, BC and LC, respectively, ranked
according to regularized t-statistics. Sample sizes were 3 per phenotype (UKOPS), and 2 per phenotype (all others). B) As A) but now in the large
sample size limit where 50% training/test partitions were used to estimate the PPV. In both A) and B), the boxplots represent the distribution of
the PPV over 50 random training/test set partitions. Wilcoxon rank sum test P-values are given.
Table 2 Study specific signal strengths and effect sizes
CANCER/NORMAL
Tissue FDR < 0.05 Effect Size
ENDOM 6967 2.57
CERVX 13616 3.45
BC 10676 1.77
LC 22239 2.19
Blood FDR < 0.05 Effect Size
UKOPS 3992 1.02
AGE
Tissue FDR < 0.05 Effect Size
OVC 57 0.49
CERVX 0 0.69
ENDOM 0 0.68
BC 591 0.72
Blood FDR < 0.05 Effect Size
UKOPS 3 0.53
T1D 294 0.61
The signal strength (measured by the number of CpGs passing an FDR
threshold < 0.05) and the average effect size (Cohen’s d = difference in
means divided by pooled standard deviation) of the top 100 ranked CpGs for
diagnosis and age-settings and for epithelial and blood tissue. Beta-values
were used to estimate effect sizes. In the case of age, samples were divided
into two groups by the median.
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Page 7 of 14than WF in two studies by approximately 5% in PPV
values, while in the diagnostic setting the worse perfor-
mance observed in two studies was far less marginal
(change in mean PPV < 1%), indicating that in cases
where effect sizes and signal strengths are small (i.e.
age), filtering based on variance can be counterproduc-
tive. Thus, we posited that in the case of cancer diag-
nostic markers in whole blood (where signal strengths
are relatively large but effect sizes are small), that VF
would also lead to a decreased PPV performance if lar-
ger evaluation sets are used since the larger evaluation
sets would include proportionally more false positives
(on account of the small effect sizes). Similarly, we
w o u l de x p e c tt h a tf o rl a r g e re v a l u a t i o ns e t st h eW F
method would allow proportionally more true positives
to be captured. Confirming this, we observed that WF
outperformed VF as the number of top ranked CpGs is
increased (Figure 4). This switch in performance
between WF and VF as a function of evaluation set size
is a consequence of the relatively small effect sizes com-
bined with the relatively large signal strengths of diag-
nostic markers in whole blood.
SPCA outperforms WF and VF when effect sizes are small
Supervised principal components has been shown to be a
simple yet powerful algorithm for performing feature
selection and classification in the gene expression context
[21]. We therefore decided to compare SPCA to the WF
and VF methods in terms of feature selection. Interest-
ingly, in the diagnostic setting SPCA did not always
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Page 8 of 14outperform VF or WF, although in all data sets it achieved
very high (> 95%) PPV values (Figure 3A). However, in the
more challenging scenario of small effect sizes and signal
strengths, as illustrated by using age as the phenotype of
interest, we can see that SPCA achieved substantially bet-
ter PPV values (Figure 3B). Thus, principal components
can identify true positives more reliably when signal
strengths are small. On the other hand, if signal strengths
are large, a principal component may not have the plasti-
city to capture all the important true positives, and thus
inevitably will include false positives among the less
weighted features within the principal component (PC).
We verified that in the diagnostic setting, SPCA PPV
values were substantially higher and comparable to those
of WF and VF when using only the top 50 CpGs in the
selected PC (Additional file 5), demonstrating that at more
relaxed feature selection thresholds SPCA includes numer-
ous false positives
Signal correlation structure is improved using beta values
Given that overall feature selection was optimal using
SPCA, we next asked if performance would be similar
had we used M-values. Remarkably, we observed that
SPCA PPV values were generally higher when evaluated
using beta values (Figure 5). This was specially true in
the diagnostic setting and was independent of tissue
type, indicating that signal strength has a major impact
on the inference of biologically relevant principal
components. Interestingly, therefore, beta-values provide
a basis in which the correlative structure of CpG methy-
lation profiles associated with cancer status is better
preserved. In contrast, in the M-value basis, it appears
that the correlation structure between biologically rele-
vant CpGs is compromised leading to worse modelling
of the biological variation.
The elastic net and SVMs outperform SPCA and LASSO
Next, we turned our attention to the classification task.
We considered a total of four different powerful classifi-
cation algorithms, including SPCA, LASSO regression,
the Elastic Net (ELNET) and support vector machines
(SVM) (Methods). We used the same training-test set
partition strategy as with our feature selection analysis.
Age was chosen as the phenotype of interest, since it is
now well established that age has an impact on DNAm
patterns [3-5,42] and because age-associated effects are
of a relatively small magnitude, thus also providing a
more challenging evaluation scenario for the classifica-
tion algorithms [3-5]. Moreover, age-associated DNAm
markers may represent cancer risk markers [3,6]. We
considered the same studies as those used for the fea-
ture selection analysis in the age setting.
Across all studies, we observed that either ELNET or
SVM were superior to LASSO and SPCA (Figure 6).
The fact that ELNET outperformed LASSO in all data
sets extends previous results obtained on gene
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Page 9 of 14expression [32] to the DNA methylation context. More-
over, we observed that SPCA always performed opti-
mally in the context of a single component (SPCA-1), i.
e. adding more principal components to the classifier
did not improve performance (Figure 6). Interestingly,
SPCA-1 performed similarly to ELNET and SVM in the
two smaller studies (ENDOM + CVX), suggesting that
the rigidity imposed by principal components can be of
an advantage in this setting.
Unsupervised modelling of diagnostic and age effects
Finally, we compared unsupervised algorithms in their
ability to model diagnostic and age effects in DNA
methylation studies. We considered two of the most
popular unsupervised dimensional reduction algorithms
from the gene expression field: singular value decompo-
sition (SVD) [43-46], and non-negative matrix factoriza-
tion (NMF) [47-51]. Given that DNA methylation beta-
valued data are defined on the compact support (0,1)
and are thus positively valued, it is justified to explore
the application of NMF in this context. To objectively
compare NMF to SVD, NMF was initialised using non-
negative double SVD, thus allowing us to determine if
the positivity constraints of the NMF framework add
biological value. For both SVD and NMF we computed
the R
2 correlations between the inferred components (or
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Page 10 of 14meta-genes) and the phenotype of interest. As a model-
ling criterion we compared the average R
2 of the two
best components, obtained from each algorithm. Focus-
ing first on the diagnostic setting, we can clearly observe
that NMF outperformed SVD/PCA in all 5 studies,
including the study comparing blood samples from can-
cers and controls (Figure 7). However, NMF was not
conclusively better in the age-setting of much smaller
effect sizes (Figure 7).
Discussion
A previous study compared b to M-values in the context
of a titration experiment using fold-change values to
rank CpGs [19]. The study concluded that M-values,
owing to their reduced heteroscedasticity, provided a
better basis in which to detect true positives. This result
is not unexpected because fold changes only consider
the magnitude of differences in mean values, regardless
of the underlying biological and technical variability.
Therefore, using b-values and fold changes, true positive
CpGs with low or high mean beta methylation values
would not be highly ranked and would result in a signif-
icant proportion of false negatives. As we have shown
here, using many different data sets and using a multiple
training test set strategy to estimate the PPV, t-statistics
derived from M-values and b-values are comparable and
lead to similar PPV values, but only in the scenario of
relatively large sample sizes. In contrast, when sample
sizes are small and a regularized t-statistic must be
used, M-values provided a significantly better basis for
inference, sometimes by as much as 10% improvements
in the PPV. That regularized t-statistics perform rela-
tively poorly in the b-value basis is not surprising, since
the regularisation involves an empirical Bayes approach
in which a posterior variance is estimated from esti-
mates specifying the prior, an approach which is known
to be more sensitive to the precise distributional proper-
ties of the data and is therefore also more sensitive to
deviations from normality. Therefore, our comprehen-
sive study using statistics to rank features, indicates that
the severe heteroscedasticity of b- v a l u e sd o e sn o tc o m -
promise the reliability of identifying true positives in the
case of relatively large sample sizes, but that M-values
offer significantly improved inference in the limit of
small sample sizes.
A second important finding is that variance filtering
does not always increase the PPV. Indeed, in scenarios
where effect sizes are small but where there are numer-
ous associated features, we have seen how variance fil-
tering can compromise the detection of true positives
when more relaxed significance thresholds are used.
This was illustrated in the context of cancer diagnostic
methylation markers in whole blood, where the changes
reflect underlying changes in blood cell type composi-
tion as demonstrated by us previously [11]. In this set-
ting, effect sizes are small but may involve a potentially
large number of genes, indeed potentially all those genes
whose expression differentiates blood cell types from
each other and whose expression is under epigenetic
regulation. Since very often there is a desire to perform
Gene Set Enrichment Analysis [54] on a set of top
ranked features, thresholds must be chosen to ensure a
relatively small false negative rate (FNR). Hence, in the
scenario described here, variance filtering may be spe-
cially counterproductive since it leads to a larger FNR
and hence could compromise the detection of enriched
GO-terms or pathways. It follows that any decision to
filter features based on variance must take into consid-
eration the clinical and biological context of the study.
Our third key result is the improved performance of
SPCA in detecting true positives, specially in the more
challenging scenario when effect sizes and signal
strengths are small. While SPCA has been shown to
outperform many other feature selection methods in the
context of gene expression data [21], an analogous result
was still lacking in the case of DNA methylation. Our
data therefore show that SPCA is a powerful feature
selection algorithm, independently of the molecular pro-
files considered or their underlying statistical distribu-
tions. The improved performance over VF also indicates
that the correlative DNAm patterns can be exploited to
identify true positives more reliably. Interestingly, we
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values. This may be surprising as one might be inclined
to believe that components of maximal variation are
more robustly identified in a basis that promotes varia-
t i o n ,i . e .u s i n gM - v a l u e s .H o w e v e r ,i ti sa l s ot h ec a s e
that M-values would aggravate the effect of outliers and
therefore distort the true components of maximal biolo-
gical variation. Therefore, Illumina’s recommendation to
use b- v a l u e so v e rM - v a l u e sa p p e a r st ob ef u r t h e rj u s t i -
fied by the fact that b-values, by virtue of being
bounded, may provide a natural regularization and thus
suppress the undesirable effects of potential technical
outliers.
We also compared various powerful classification
algorithms, including SPCA, ELNET, LASSO and SVMs.
Our results clearly indicate that ELNET and SVM are
superior classification methods in the case where effect
sizes are small. Given that ELNET also provides an
automatic means of feature selection (i.e. those features
with non-zero regression coefficients), it would appear
to be a preferable choice over SVM. Nevertheless, SVM
outperformed ELNET in three studies, including the
two smaller ones (ENDOM + CVX). Interestingly, we
also observed that classification using SPCA performed
optimally in the context of a single component of varia-
tion (SPCA-1). Since multi-component SPCA (SPCA-2,
3) uses a training set to estimate an optimal linear com-
bination of principal components that then makes up
the predictor, it would appear that the estimated weights
specifying the linear combination is not mirrored in the
test set, hence why SPCA-1 is optimal. It will be inter-
esting to investigate if this result generalizes to other
phenotypes where effect sizes may be small.
Finally, we also compared two of the most popular
unsupervised algorithms (SVD and NMF) in their ability
to model differences between cancer and normal tissues
and differences associated with age. Similar to the
results obtained on gene expression, we observed that
NMF also outperforms SVD/PCA in the context of
DNA methylation data. Indeed, the meta-genes inferred
from the NMF were generally more highly correlated
with cancer/normal status across all data sets consid-
ered. Hence, despite the increased computational com-
plexity of NMF, this algorithm should be used whenever
expected effect sizes are large. On the other hand, if
effect sizes are small (age-setting) we did not find that
the increased computational complexity of NMF offered
any advantage over PCA.
In the context of evaluating feature selection and
classification methods, it is important to discuss the
impact of potential batch effects. Indeed, as shown in
many previous papers [55-59], known and unknown
batch effects can affect a substantial proportion of
features in an experiment and lead to biased estimates
of statistical significance. In this work we used inter-
array normalised data where beadchip effects and var-
iations in bisulfite conversion efficiency were adjusted
for using a linear model framework, as these factors
were observed to account for significant components of
variation in PCA analysis (see e.g. [11]). We observed
that not correcting for these factors may alter the abso-
lute performance of any given method, yet the relative
performance of the different methods was largely
robust to whether inter-array normalisation was per-
formed or not (data not shown). Since the inter-array
normalisation used only adjusts for known effects (i.e.
beadchip and bisulfite conversion efficiency), we have
not considered here the potential effects of unknown
confounders. To address this would require adapting
Surrogate Variable Analysis (SVA) approaches [55,59]
in the training/test set evaluation framework consid-
ered here. This has only very recently made possible
through an extension of SVA, called frozen SVA [60].
Thus, it will be interesting to further compare these
feature selection methods in the context of the present
DNA methylation data sets, and thus further assess the
potential impact of (unknown) batch effects on feature
selection and classification.
While the insights obtained in this study have been
derived from one particular array (the 27k Infinium
beadchip), it is likely that similar insights would apply
to the recently released scaled up 450k Infinium bead-
chip [10,35]. We should point out however, that one of
the key differences between the 27k and 450k plat-
forms is that the probes on the 450k beadarray come
in two different designs and are thus characterised by
widely different statistical distributions [61]. Thus, the
insights obtained here are likely to apply only to the
data restricted to probes of one particular design. In
any case, the much higher density of the 450k array
(over 480,000 features compared to ~27,000), means
that feature selection in 450k data will be even more
critical.
Conclusions
The optimal choice of methylation measure and feature
selection method in the context of 27k DNA methyla-
tion data is dependent on the sample size, expected
effect sizes and signal strength of the specific study.
While SPCA is a powerful feature selection tool in DNA
methylation studies where effect sizes and signal
strengths are small, the Elastic Net and SVMs generally
outperform SPCA in the context of classification. These
insights are important for anyone embarking on large
scale DNA methylation profiling using 27k or 450k
beadarrays.
Zhuang et al. BMC Bioinformatics 2012, 13:59
http://www.biomedcentral.com/1471-2105/13/59
Page 12 of 14Additional material
Additional file 1: Typical scatterplots of mean methylation (x-axis)
vs standard deviation in methylation (y-axis) using beta (left
panels) and M values (right panels). Green line denotes a mean loess
smoother. A) The blood samples from the 148 healthy controls in the
UKOPS study. B) The 187 blood samples from the T1D study.
Additional file 2: False discovery rate (FDR) estimation table at
different thresholds of top cancer diagnostic associated CpGs
obtained from the supervised analysis (without filtering) in the
UKOPS, ENDOM, and CERVX data sets.
Additional file 3: The evaluation set size (y-axis) is plotted against
the mean PPV (x-axis) for the different studies. The mean PPV
represents an average over the 50 training-test partitions and over
the 3 feature selection methods (WF, VF and SPCA). A) Diagnostic
setting, B) Age setting. The selected evaluation set sizes in each study
and for each phenotype of interest are marked in red. Note that in the
case of age, differences in mean PPV between studies could not be
minimized because of the additional constraint of a reasonable minimum
set size.
Additional file 4: A-B) Comparison of positive predictive values
(PPV) obtained from beta (red) and m-values (green) using the
without-filtering method and using 50 training-test set partitions
(each boxplot contains 50 data points). A) Diagnosis setting in UKOPS,
ENDOM, CERVX, BC and LC with evaluation set sizes of top 200, 1500,
2500, 1500, and 3000 diagnosis-associated-CpGs, respectively; and B) Age
setting in T1D, OVC, CERVX, UKOPS, ENDOM, and BC with the top 1000,
500, 200, 500, 200, and 1500 age-associated-CpGs as evaluation sets,
respectively. C-D) Comparison of absolute t-statistics obtained from beta
and m-values. C) Diagnostic setting in UKOPS, ENDOM, CERVX, BC and
LC; and D) age setting in T1D, OVC, CERVX, UKOPS, ENDOM, and BC. All
p-values shown are from a Wilcoxon-rank sum test.
Additional file 5: Mean PPV values between SPCA, WF and VF in
the diagnostic setting but using only the top ranked 50 CpGs as
evaluation sets.
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